Form 4: Day One Biopharmaceuticals Acquired by Servier

Director John A. Josey reports the disposal of all equity holdings following the successful acquisition of Day One Biopharmaceuticals by Servier Pharmaceuticals.

Summary

• Day One Biopharmaceuticals, Inc. (DAWN) has been acquired by Servier Pharmaceuticals LLC.
• The merger was finalized on April 23, 2026.
• Reporting person John A. Josey disposed of 72,292 shares of common stock at the merger consideration price of $21.50 per share.
• All outstanding stock options and restricted stock units (RSUs) held by the director were fully vested immediately prior to the merger and converted into cash payments based on the merger consideration.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for the market, as it represents the final administrative step of a completed corporate acquisition.

Positives

• Shareholders received a cash consideration of $21.50 per share.
• All unvested equity awards were accelerated and vested in full upon the closing of the merger.

Negatives

• The company is no longer a publicly traded entity as it has become a wholly owned subsidiary of Servier Pharmaceuticals.

Risks

• None, as the company has been acquired and is no longer a standalone public entity.

Future Outlook

The company is now a wholly owned subsidiary of Servier Pharmaceuticals; therefore, no further public guidance or forward-looking statements will be provided by the entity.

Industry Context

StockSavvy.ai notes that this acquisition reflects the ongoing trend of consolidation in the biopharmaceutical sector, where larger established players like Servier are acquiring mid-cap firms to bolster their oncology and specialty drug pipelines.

Comparison to Industry Standards

• The $21.50 per share cash exit is consistent with standard M&A premiums observed in the biotech sector for companies with late-stage clinical assets.
• The acceleration of unvested equity is a standard change-of-control provision in executive compensation agreements.

Legal Proceedings

• The company entered into a definitive Merger Agreement with Servier Pharmaceuticals LLC and its affiliates.

Stakeholder Impact

• Shareholders have been cashed out at the agreed merger price.
• Employees and management are now part of the Servier Pharmaceuticals organization.

Next Steps

• Delisting of DAWN common stock from public exchanges.

Key Dates

Keywords

Day One Biopharmaceuticals, DAWN, Servier Pharmaceuticals, Merger, Acquisition, Form 4, Insider Transaction